SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Ede )
Also on site :
- India-Pakistan deadly fighting forces airlines to re-route, cancel flights
- Kremlin comments on ceasefire plans after Ukrainian drone strikes
- Bitcoin consolidates above a key level as all-time highs continue to be in sight